MM-302

DRUG2 trials

Sponsors

Merrimack Pharmaceuticals, Pamela Munster

Conditions

Advanced Solid TumorBrain MetastasesBreast CancerDocumented Her2 OverexpressionHER2 Positive Breast CancerNeurologically Stable

Early Phase 1

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

WithdrawnNCT02735798

Pamela MunsterAdvanced Solid Tumor, Brain Metastases, Documented Her2 Overexpression +1

Start: 2016-04-30End: 2018-06-30Updated: 2017-05-04

Phase 2

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

TerminatedNCT02213744

Merrimack PharmaceuticalsBreast Cancer, HER2 Positive Breast Cancer

Start: 2014-07-31End: 2017-06-30Updated: 2017-01-06

Related Papers

Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo

Cancer Research2016-07-15

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

2016-06-03103 citations

HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Journal of Clinical Oncology2016-05-203 citations

Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)

Cancer Research2016-02-152 citations

HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Journal of Clinical Oncology2015-05-203 citations